12:00 AM
Dec 18, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GPI-15715 (PQ-1002): Began Phase I trial

Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md.
Product: GPI-15715 (PQ-1002)
Business: Neurological
Therapeutic category: Neurotransmission
Target: Unknown
Description: Water soluble...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >